title: Testicular cancer in 2013: towards personalized medicine--are we there yet?
abstract: The pursuit of reduced-intensity treatments for testicular cancer continued with vigour in 2013. For those with metastatic disease and poor prognoses, an alternative to bleomycin, etoposide and cisplatin chemotherapy emerged. These advances suggest we are making progress by reducing treatment intensity with personalized approaches for this highly curable malignancy.
authors.affiliation: Department of Oncology, Oslo University Hospital, Ullernchausseen 70, Oslo 0313, Norway.
authors.forename: Jan
authors.initials: J
authors.lastname: Oldenburg
authors.affiliation: Department of Oncology, Oslo University Hospital, Ullernchausseen 70, Oslo 0313, Norway.
authors.forename: Sophie D
authors.initials: SD
authors.lastname: Fosså
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy* / Q000601:surgery*; D016609:Neoplasms, Second Primary / Q000453:epidemiology*; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000601:surgery*